Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

来那度胺 医学 安慰剂 骨髓增生异常综合症 内科学 贫血 临床终点 红细胞生成 胃肠病学 促红细胞生成素 耐火材料(行星科学) 随机对照试验 外科 多发性骨髓瘤 骨髓 病理 物理 替代医学 天体生物学
作者
Valeria Santini,António Almeida,Aristoteles Giagounidis,Stefanie Gröpper,Anna Jonášová,Norbert Vey,Ghulam J. Mufti,Rena Buckstein,Moshe Mittelman,Uwe Platzbecker,Ofer Shpilberg,Ron Ram,Consuelo del Cañizo,Norbert Gattermann,Keiya Ozawa,Alberto Risueño,Kyle J. MacBeth,Judy Zhong,Francis Séguy,Albert Hoenekopp,C.L. Beach,Pierre Fenaux
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:34 (25): 2988-2996 被引量:206
标识
DOI:10.1200/jco.2015.66.0118
摘要

This international phase III, randomized, placebo-controlled, double-blind study assessed the efficacy and safety of lenalidomide in RBC transfusion-dependent patients with International Prognostic Scoring System lower-risk non-del(5q) myelodysplastic syndromes ineligible for or refractory to erythropoiesis-stimulating agents.In total, 239 patients were randomly assigned (2:1) to treatment with lenalidomide (n = 160) or placebo (n = 79) once per day (on 28-day cycles). The primary end point was the rate of RBC transfusion independence (TI) ≥ 8 weeks. Secondary end points were RBC-TI ≥ 24 weeks, duration of RBC-TI, erythroid response, health-related quality of life (HRQoL), and safety.RBC-TI ≥ 8 weeks was achieved in 26.9% and 2.5% of patients in the lenalidomide and placebo groups, respectively (P < .001). Ninety percent of patients achieving RBC-TI responded within 16 weeks of treatment. Median duration of RBC-TI with lenalidomide was 30.9 weeks (95% CI, 20.7 to 59.1). Transfusion reduction of ≥ 4 units packed RBCs, on the basis of a 112-day assessment, was 21.8% in the lenalidomide group and 0% in the placebo group. Higher response rates were observed in patients with lower baseline endogenous erythropoietin ≤ 500 mU/mL (34.0% v 15.5% for > 500 mU/mL). At week 12, mean changes in HRQoL scores from baseline did not differ significantly between treatment groups, which suggests that lenalidomide did not adversely affect HRQoL. Achievement of RBC-TI ≥ 8 weeks was associated with significant improvements in HRQoL (P < .01). The most common treatment-emergent adverse events were neutropenia and thrombocytopenia.Lenalidomide yields sustained RBC-TI in 26.9% of RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes ineligible for or refractory to erythropoiesis-stimulating agents. Response to lenalidomide was associated with improved HRQoL. Treatment-emergent adverse event data were consistent with the known safety profile of lenalidomide.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Joyhold发布了新的文献求助10
刚刚
猩猩完成签到,获得积分10
刚刚
2秒前
3秒前
3秒前
Maestro_S的应助被时平谊采纳,获得200
3秒前
3秒前
乐乐的应助被时平谊采纳,获得10
3秒前
rio发布了新的文献求助10
3秒前
orixero的应助被369ninja采纳,获得10
5秒前
郭姗姗发布了新的文献求助10
5秒前
5秒前
无聊的依白完成签到,获得积分10
6秒前
6秒前
zzz发布了新的文献求助10
6秒前
脑洞疼的应助被乔清采纳,获得30
7秒前
柠浩完成签到,获得积分10
8秒前
10秒前
别玉玉发布了新的文献求助10
10秒前
zhou完成签到,获得积分10
10秒前
11秒前
ayang123发布了新的文献求助10
11秒前
11秒前
12秒前
小怪完成签到,获得积分10
12秒前
春深完成签到,获得积分10
12秒前
星星蘸大酱完成签到,获得积分10
12秒前
13秒前
Aintzane完成签到,获得积分10
14秒前
机灵纸鹤发布了新的文献求助30
15秒前
明理的鼠标完成签到,获得积分10
15秒前
JohnRyan发布了新的文献求助10
16秒前
17秒前
桃博发布了新的文献求助10
17秒前
Joyhold发布了新的文献求助10
17秒前
nicai完成签到,获得积分10
18秒前
丘比特的应助被throb采纳,获得10
18秒前
20秒前
21秒前
科研通AI6.3的应助被柠浩采纳,获得10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177849
求助须知:如何正确求助?哪些是违规求助? 9568641
关于积分的说明 21800145
捐赠科研通 7772473
什么是DOI,文献DOI怎么找? 3432537
关于科研通互助平台的介绍 2556720
邀请新用户注册赠送积分活动 2478067